Taking people in NetherlandsPhase 4
Pembrolizumab for People With Metastatic Cervical Cancer: Tracking Outcomes
Studies pembrolizumab in adults with metastatic cervical cancer, tracking disease progression at 12 months.
Key facts
- Who runs it
- Universitair Medisch Centrum Groningen
- Where
- Amsterdam, Eindhoven, Enschede, Groningen, Leiden, Maastricht, Nijmegen, Rotterdam, Utrecht, and Zwolle, NetherlandsSee the 11 sites
- Trial code
- Registry title
- PROTECx - Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 261 people, planned
- Started
- 12 Jun 2026
- Expected to end
- 1 Apr 2039
- Type of study
- Interventional
- Record updated
- 11 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women with cervical cancer that keeps coming back, has returned or has spread, and who are starting or already having a treatment that contains pembrolizumab. A second group are women from this study who choose to stop pembrolizumab.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- Cervical cancer that is persistent, has come back, or has spread (metastatic).
- Earlier treatment
- Observation group: starting or currently on a treatment that contains pembrolizumab. Stop-early group: already in the observation group and ready to stop pembrolizumab, with or without bevacizumab.
Main reasons for not taking part
- Another cancer that needed active treatment in the past 2 years (some skin cancers and carcinoma in situ treated with potentially curative therapy do not count)
- Any condition that, in the investigator's opinion, may make it hard to follow the study procedures
- Not enough written and spoken Dutch to understand the study information, fill in the questionnaires or give consent
The registry criteria, word for word
Show all 3 criteriaShow less
Who cannot take part
- Malignant other disease other than cervical carcinoma that required active treatment in the past 2 years: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, transitional cell carcinoma of urothelial cancer, or any carcinoma in situ that have undergone potentially curative therapy are not excluded
- Any condition, in opinion of the investigator, that may hamper compliance to the study procedures
- Insufficient proficiency in written and spoken Dutch to understand the study information, complete Dutch language questionnaires, or provide informed consent will be excluded
Where in Netherlands
- Amsterdam UMC StichtingAmsterdam, NetherlandsTaking people
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingAmsterdam, NetherlandsTaking people
- Catharina Ziekenhuis StichtingEindhoven, NetherlandsTaking people
- Medisch Spectrum TwenteEnschede, NetherlandsTaking people
- Universitair Medisch Centrum GroningenGroningen, NetherlandsTaking people
- Leids Universitair Medisch Centrum (LUMC)Leiden, NetherlandsTaking people
- Academisch Ziekenhuis MaastrichtMaastricht, NetherlandsTaking people
- Radboud universitair medisch centrum StichtingNijmegen, NetherlandsTaking people
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, NetherlandsTaking people
- Universitair Medisch Centrum UtrechtUtrecht, NetherlandsTaking people
- Isala Klinieken StichtingZwolle, NetherlandsTaking people
About the trial
What the trial wants to find out
• To evaluate the PFS at 12 months and compare to the historical PFS of the KEYNOTE-826 trial.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- PROTECx - Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer
- Plain-language title
- Pembrolizumab for People With Metastatic Cervical Cancer: Tracking OutcomesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 11 November 2026.
- Record updated
- 11 May 2026